Consensus estimates from Visible Alpha suggest AstraZeneca will report sales of $15.505 billion, marking an increase from the $14.89 billion recorded during the same period last year. Core earnings per share, the company's preferred metric that excludes one-off items, are projected to reach $2.11, a slight uptick from $2.09 a year ago. This financial steadying follows a strong performance in the equity markets, where shares rose 11% in the final quarter of the year.

The $15 Billion Weight-Loss Gamble

The central theme for the upcoming report is AstraZeneca’s attempt to break the duopoly of Eli Lilly and Novo Nordisk in the weight-loss sector. The company recently committed $1.2 billion upfront to acquire China-based CSPC Pharmaceuticals, securing rights to experimental obesity and diabetes drugs. According to the biopharma database DealForma, the total potential value of the agreement could exceed $15 billion, making it the largest deal of its kind by total potential value.

Despite the scale of the deal, some analysts remain cautious regarding the timing and cost. Macquarie analysts Candyce Gao and Tony Ren noted that the upfront payment is "particularly large" for assets still in their early stages. Beyond obesity, the company is under pressure to prove it can hit a $80 billion revenue target by 2030. Achieving this goal depends on several critical factors:

• The success of clinical trial readouts scheduled between 2027 and 2029.
• Navigating U.S. patent expirations that threaten existing revenue streams.
• Managing the impact of China’s drug-purchase policies and rising research costs.

AJ Bell analyst Russ Mould indicated that pipeline strength will be the deciding factor in whether the company can maintain its momentum beyond Tuesday and into the next decade. As existing drugs face generic competition, the market will look for clarity on how new research and development investments will bridge the gap to peak sales potential.